Market capitalization | $3.13b |
Enterprise Value | $4.02b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 548.17 |
P/S ratio (TTM) P/S ratio | 426.84 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | 1,218.71% |
Revenue (TTM) Revenue | $7.33m |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
3 Analysts have issued a ImmunityBio Inc forecast:
3 Analysts have issued a ImmunityBio Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 7.33 7.33 |
1,209%
1,209%
|
|
Gross Profit | -11 -11 |
55%
55%
|
|
EBITDA | -341 -341 |
1%
1%
|
EBIT (Operating Income) EBIT | -359 -359 |
0%
0%
|
Net Profit | -588 -588 |
28%
28%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in Culver City, CA.
Head office | United States |
CEO | Richard Adcock |
Employees | 628 |
Founded | 2014 |
Website | www.immunitybio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.